RxDoctor Payments Data

Saad Ahmad, MD

Advanced Heart Failure and Transplant Cardiology · Morristown, NJNPI 1811150816

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (37.3%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 48 manufacturers reported payments, led by Pfizer at 36.0% of the total. 2025 is the largest year on record at $24,098, 5.7 times the $4,234 reported in 2019.

$74,193in general payments, 2019–2025

Across 437 payments — averaging $169.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$27K
  • Abbott$11K
  • Shockwave Medical, Inc$11K
  • Bayer$8K
  • Inari Medical, Inc.$4K
  • Boston Scientific$3K
  • plus $11K from 42 others
$293,321in research payments, 2019–2025

Across 107 payments — averaging $2741.32 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • CSL Behring$82K
  • Boehringer Ingelheim International GmbH$55K
  • Procyrion, Inc.$52K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$33K
  • Inari Medical, Inc.$28K
  • Abbott$21K
  • plus $24K from 5 others

What the payments were for

  • Consulting fees$15,04420%
  • Speaking & faculty fees$27,64837%
  • Travel & lodging$10,64214%
  • Food & beverage$20,76328%
  • Education$970%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$74,193 in reported general payments places this provider in the 80th percentile of 21 advanced heart failure and transplant cardiology providers in New Jersey.

See all advanced heart failure and transplant cardiology providers in New Jersey

Medicare billing

Part B allowed, 2024
$68,243
Medicare patients
153
Services billed
422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan63$56,484
JardianceEmpagliflozin36$36,374
Isosorbide Mononitrate ErIsosorbide Mononitrate57$858
Atorvastatin Calcium79$806
Torsemide25$776
Hydralazine Hcl13$639
Rosuvastatin Calcium56$619
Potassium Chloride18$473
Ezetimibe24$467
Metoprolol Succinate49$459
ClopidogrelClopidogrel Bisulfate45$319
Pravastatin Sodium11$266
Spironolactone36$261
Carvedilol41$245
Furosemide52$199

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$69$56,48463 claims
Boehringer IngelheimJardiance$142$36,37436 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 21 advanced heart failure and transplant cardiology providers in New Jersey.

Other advanced heart failure and transplant cardiology in Morristown

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →